Halozyme Therapeutics Statistics
Share Statistics
Halozyme Therapeutics has 123.22M
shares outstanding. The number of shares has increased by -2.94%
in one year.
| Shares Outstanding | 123.22M |
| Shares Change (YoY) | -2.94% |
| Shares Change (QoQ) | -2.9% |
| Owned by Institutions (%) | 97.48% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 5,512 |
| FTD / Avg. Volume | 0.25% |
Short Selling Information
The latest short interest is 10.69M, so 8.68% of the outstanding
shares have been sold short.
| Short Interest | 10.69M |
| Short % of Shares Out | 8.68% |
| Short % of Float | 11.87% |
| Short Ratio (days to cover) | 2.36 |
Valuation Ratios
The PE ratio is 13.65 and the forward
PE ratio is 7.77.
Halozyme Therapeutics's PEG ratio is
0.21.
| PE Ratio | 13.65 |
| Forward PE | 7.77 |
| PS Ratio | 5.97 |
| Forward PS | 3.6 |
| PB Ratio | 16.67 |
| P/FCF Ratio | 12.95 |
| PEG Ratio | 0.21 |
Financial Ratio HistoryEnterprise Valuation
Halozyme Therapeutics has an Enterprise Value (EV) of 7.45B.
| EV / Sales | 7.34 |
| EV / EBITDA | 11.35 |
| EV / EBIT | 15.56 |
| EV / FCF | 15.91 |
Financial Position
The company has a current ratio of 7.8,
with a Debt / Equity ratio of 4.14.
| Current Ratio | 7.8 |
| Quick Ratio | 6.78 |
| Debt / Equity | 4.14 |
| Debt / EBITDA | 2.29 |
| Debt / FCF | 3.21 |
| Interest Coverage | 30.48 |
Financial Efficiency
Return on Equity is 122.06% and Return on Invested Capital is 22.84%.
| Return on Equity | 122.06% |
| Return on Assets | 21.52% |
| Return on Invested Capital | 22.84% |
| Revenue Per Employee | $2,900,925.71 |
| Profits Per Employee | $1,268,831.43 |
| Employee Count | 350 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 1.12 |
Taxes
| Income Tax | 113.04M |
| Effective Tax Rate | 20.29% |
Stock Price Statistics
The stock price has increased by 20.38% in the
last 52 weeks. The beta is 1.19, so Halozyme Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.19 |
| 52-Week Price Change | 20.38% |
| 50-Day Moving Average | 59.04 |
| 200-Day Moving Average | 56.36 |
| Relative Strength Index (RSI) | 42.33 |
| Average Volume (20 Days) | 2,189,069 |
Income Statement
In the last 12 months, Halozyme Therapeutics had revenue of 1.02B
and earned 444.09M
in profits. Earnings per share was 3.5.
| Revenue | 1.02B |
| Gross Profit | 855.91M |
| Operating Income | 551.48M |
| Net Income | 444.09M |
| EBITDA | 656.54M |
| EBIT | 575.23M |
| Earnings Per Share (EPS) | 3.5 |
Full Income StatementBalance Sheet
The company has 115.85M in cash and 1.51B in
debt, giving a net cash position of -1.39B.
| Cash & Cash Equivalents | 115.85M |
| Total Debt | 1.51B |
| Net Cash | -1.39B |
| Retained Earnings | 359.87M |
| Total Assets | 2.2B |
| Working Capital | 1.11B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 479.06M
and capital expenditures -10.7M, giving a free cash flow of 468.37M.
| Operating Cash Flow | 479.06M |
| Capital Expenditures | -10.7M |
| Free Cash Flow | 468.37M |
| FCF Per Share | 3.69 |
Full Cash Flow StatementMargins
Gross margin is 84.3%, with operating and profit margins of 54.32% and 43.74%.
| Gross Margin | 84.3% |
| Operating Margin | 54.32% |
| Pretax Margin | 54.87% |
| Profit Margin | 43.74% |
| EBITDA Margin | 64.66% |
| EBIT Margin | 54.32% |
| FCF Margin | 46.13% |
